Association between levothyroxine treatment for maternal subclinical hypothyroidism with negative TPOAb and early child neurodevelopment: A prospective real‐world clinical trial

Abstract Introduction Subclinical hypothyroidism (SCH) during pregnancy is reported to have detrimental impact on pregnancy and child development. However, its treatment indications require further investigation in different thyroid peroxidase antibody (TPOAb) status. Material and methods This was a...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhekun Zhao, Qiongjie Zhou, Huanqiang Zhao, Yu Xiong, Xiaotian Li
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Acta Obstetricia et Gynecologica Scandinavica
Subjects:
Online Access:https://doi.org/10.1111/aogs.14602
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850211623962148864
author Zhekun Zhao
Qiongjie Zhou
Huanqiang Zhao
Yu Xiong
Xiaotian Li
author_facet Zhekun Zhao
Qiongjie Zhou
Huanqiang Zhao
Yu Xiong
Xiaotian Li
author_sort Zhekun Zhao
collection DOAJ
description Abstract Introduction Subclinical hypothyroidism (SCH) during pregnancy is reported to have detrimental impact on pregnancy and child development. However, its treatment indications require further investigation in different thyroid peroxidase antibody (TPOAb) status. Material and methods This was a secondary analysis of a Chinese prospective cohort in a real‐world setting. Pregnant women with gestational SCH were enrolled at the first antenatal visit and grouped by TPOAb positivity. Child neurodevelopment was assessed by the Gesell development diagnosis scale (GDDS) at one, three, six, 12, and 24 months of age. Subgroup analyses and sensitivity analyses were also conducted. Clinical trial registration: ClinicalTrials.gov NCT01744743. Results From January 2012 to December 2013, a total of 171 participants were enrolled, including 116 of SCH with TPOAb negative (SCH‐TPOAb [−]) and 55 of SCH with TPOAb positive (SCH‐TPOAb [+]). Compared to women in the SCH‐TPOAb (+) group, those in the SCH‐TPOAb (−) group had lower thyroid‐stimulating hormone (TSH) levels at enrollment and 12–16+6 gestational weeks, and unexpectedly higher TSH levels at 30–34+6 gestational weeks and delivery, with a correspondingly lower levothyroxine dosage throughout pregnancy (all p < 0.05). Offspring in the SCH‐TPOAb (−) group displayed lower GDDS scores at one year old than did their counterparts (adjusted p < 0.05), which was possibly related to the worse thyroid function control of maternal SCH‐TPOAb (−). No statistically significant difference was found in the GDDS assessments of children at one, three, six, and 24 months of age. These results were also confirmed in subgroup analyses stratified by maternal thyroid characteristics at enrollment, namely TSH levels, free levothyroxine (T4) levels, and anti‐thyroglobulin antibody (TgAb) status, as well as in sensitivity analyses excluding participants with no levothyroxine treatment at enrollment. Conclusions In the current clinical practice, infants born to mothers with SCH‐TPOAb (−) displayed slightly lower neurodevelopmental scores at one year old than did those born to mothers with SCH‐TPOAb (+) but this difference was not seen at two years.
format Article
id doaj-art-8ccfd3fcf65041eb9615d7a10f90d412
institution OA Journals
issn 0001-6349
1600-0412
language English
publishDate 2023-09-01
publisher Wiley
record_format Article
series Acta Obstetricia et Gynecologica Scandinavica
spelling doaj-art-8ccfd3fcf65041eb9615d7a10f90d4122025-08-20T02:09:31ZengWileyActa Obstetricia et Gynecologica Scandinavica0001-63491600-04122023-09-0110291183119210.1111/aogs.14602Association between levothyroxine treatment for maternal subclinical hypothyroidism with negative TPOAb and early child neurodevelopment: A prospective real‐world clinical trialZhekun Zhao0Qiongjie Zhou1Huanqiang Zhao2Yu Xiong3Xiaotian Li4Department of Obstetrics Obstetrics and Gynecology Hospital of Fudan University Shanghai ChinaDepartment of Obstetrics Obstetrics and Gynecology Hospital of Fudan University Shanghai ChinaDepartment of Obstetrics Obstetrics and Gynecology Hospital of Fudan University Shanghai ChinaDepartment of Obstetrics Obstetrics and Gynecology Hospital of Fudan University Shanghai ChinaDepartment of Obstetrics Obstetrics and Gynecology Hospital of Fudan University Shanghai ChinaAbstract Introduction Subclinical hypothyroidism (SCH) during pregnancy is reported to have detrimental impact on pregnancy and child development. However, its treatment indications require further investigation in different thyroid peroxidase antibody (TPOAb) status. Material and methods This was a secondary analysis of a Chinese prospective cohort in a real‐world setting. Pregnant women with gestational SCH were enrolled at the first antenatal visit and grouped by TPOAb positivity. Child neurodevelopment was assessed by the Gesell development diagnosis scale (GDDS) at one, three, six, 12, and 24 months of age. Subgroup analyses and sensitivity analyses were also conducted. Clinical trial registration: ClinicalTrials.gov NCT01744743. Results From January 2012 to December 2013, a total of 171 participants were enrolled, including 116 of SCH with TPOAb negative (SCH‐TPOAb [−]) and 55 of SCH with TPOAb positive (SCH‐TPOAb [+]). Compared to women in the SCH‐TPOAb (+) group, those in the SCH‐TPOAb (−) group had lower thyroid‐stimulating hormone (TSH) levels at enrollment and 12–16+6 gestational weeks, and unexpectedly higher TSH levels at 30–34+6 gestational weeks and delivery, with a correspondingly lower levothyroxine dosage throughout pregnancy (all p < 0.05). Offspring in the SCH‐TPOAb (−) group displayed lower GDDS scores at one year old than did their counterparts (adjusted p < 0.05), which was possibly related to the worse thyroid function control of maternal SCH‐TPOAb (−). No statistically significant difference was found in the GDDS assessments of children at one, three, six, and 24 months of age. These results were also confirmed in subgroup analyses stratified by maternal thyroid characteristics at enrollment, namely TSH levels, free levothyroxine (T4) levels, and anti‐thyroglobulin antibody (TgAb) status, as well as in sensitivity analyses excluding participants with no levothyroxine treatment at enrollment. Conclusions In the current clinical practice, infants born to mothers with SCH‐TPOAb (−) displayed slightly lower neurodevelopmental scores at one year old than did those born to mothers with SCH‐TPOAb (+) but this difference was not seen at two years.https://doi.org/10.1111/aogs.14602child neurodevelopmentGesell development diagnosis scalelevothyroxinepregnancysubclinical hypothyroidismthyroid peroxidase antibody
spellingShingle Zhekun Zhao
Qiongjie Zhou
Huanqiang Zhao
Yu Xiong
Xiaotian Li
Association between levothyroxine treatment for maternal subclinical hypothyroidism with negative TPOAb and early child neurodevelopment: A prospective real‐world clinical trial
Acta Obstetricia et Gynecologica Scandinavica
child neurodevelopment
Gesell development diagnosis scale
levothyroxine
pregnancy
subclinical hypothyroidism
thyroid peroxidase antibody
title Association between levothyroxine treatment for maternal subclinical hypothyroidism with negative TPOAb and early child neurodevelopment: A prospective real‐world clinical trial
title_full Association between levothyroxine treatment for maternal subclinical hypothyroidism with negative TPOAb and early child neurodevelopment: A prospective real‐world clinical trial
title_fullStr Association between levothyroxine treatment for maternal subclinical hypothyroidism with negative TPOAb and early child neurodevelopment: A prospective real‐world clinical trial
title_full_unstemmed Association between levothyroxine treatment for maternal subclinical hypothyroidism with negative TPOAb and early child neurodevelopment: A prospective real‐world clinical trial
title_short Association between levothyroxine treatment for maternal subclinical hypothyroidism with negative TPOAb and early child neurodevelopment: A prospective real‐world clinical trial
title_sort association between levothyroxine treatment for maternal subclinical hypothyroidism with negative tpoab and early child neurodevelopment a prospective real world clinical trial
topic child neurodevelopment
Gesell development diagnosis scale
levothyroxine
pregnancy
subclinical hypothyroidism
thyroid peroxidase antibody
url https://doi.org/10.1111/aogs.14602
work_keys_str_mv AT zhekunzhao associationbetweenlevothyroxinetreatmentformaternalsubclinicalhypothyroidismwithnegativetpoabandearlychildneurodevelopmentaprospectiverealworldclinicaltrial
AT qiongjiezhou associationbetweenlevothyroxinetreatmentformaternalsubclinicalhypothyroidismwithnegativetpoabandearlychildneurodevelopmentaprospectiverealworldclinicaltrial
AT huanqiangzhao associationbetweenlevothyroxinetreatmentformaternalsubclinicalhypothyroidismwithnegativetpoabandearlychildneurodevelopmentaprospectiverealworldclinicaltrial
AT yuxiong associationbetweenlevothyroxinetreatmentformaternalsubclinicalhypothyroidismwithnegativetpoabandearlychildneurodevelopmentaprospectiverealworldclinicaltrial
AT xiaotianli associationbetweenlevothyroxinetreatmentformaternalsubclinicalhypothyroidismwithnegativetpoabandearlychildneurodevelopmentaprospectiverealworldclinicaltrial